摘要
阿尔茨海默病(AD)是老年人中引起痴呆最常见的一种慢性神经退行性疾病。目前AD发病机制不明确,没有有效的治疗手段,现有的治疗仅局限在缓解症状。因此研发有效的AD治疗药物迫在眉睫。本文根据公开发表的文献,对目前全球已经完成和正在进行Ⅰ、Ⅱ、Ⅲ期临床试验的AD治疗药物进行了总结,众多临床试验失败的教训提示单一靶点的治疗对于AD这种复杂疾病很难奏效。而多靶点药物和鸡尾酒组方药物可能是未来AD药物研发的一个重要方向。此外通过小分子化合物促进神经再生也可能是一种新的研发策略。中国在天然产物研究方面具有得天独厚的优势,很多天然产物都具有多靶点的药理学活性,并且对神经再生有促进作用,都值得进一步深入开发。
Alzheimer's disease(AD) is a chronic progressive neurodegenerative disease. The pathogenesis of AD is unclear, and it is presently incurable. Medicines currently available for AD treatment are only for improving the cognitive symptoms, but not able to stop or delay disease progression. Here, we summarized the interventions in early phases of AD in clinical trial. As a complex disease, AD is difficult to be restored through a treatment on a single target. Multi-target and cocktail drugs might be a strategy for development of AD therapies. In addition, AD is characterized by progressive neuronal loss in the cortex and hippocampus. The induction of neurogenesis by small molecule compounds has drawn attention in the AD field. The study of natural products in China is leading the way in the AD world. Numerous natural products have been identified for pharmacological effects on multi-targets in the regulation of neurogenic activity, which may open up a new avenue for AD treatments.
出处
《药学学报》
CAS
CSCD
北大核心
2016年第8期1185-1195,共11页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(81473200)
国家"重大新药创制"科技重大专项资助项目(2012ZX09301002-004
2014ZX09507003-001)